Graham S Taylor

List of Publications by Year
in descending order

58	13,191	159358	149479
papers	citations	30 h-index	56 g-index

65	65	65	25731
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
3	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	4.3	2,064
4	Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr Virus. Annual Review of Immunology, 2007, 25, 587-617.	9.5	668
5	The Immunology of Epstein-Barr Virusâ€“Induced Disease. Annual Review of Immunology, 2015, 33, 787-821.	9.5	416
6	Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epsteinâ€“Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. Cancer Research, 2013, 73, 1676-1688.	0.4	159
7	CD8 T Cell Recognition of Endogenously Expressed Epstein-Barr Virus Nuclear Antigen 1. Journal of Experimental Medicine, 2004, 199, 1409-1420.	4.2	153
8	Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 2022, 23, 40-49.	7.0	145
9	A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epsteinâ€“Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. Clinical Cancer Research, 2014, 20, 5009-5022.	3.2	139
10	Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2165-2170.	3.3	101
11	Immune defence against EBV and EBV-associated disease. Current Opinion in Immunology, 2011, 23, 258-264.	2.4	91
12	Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma. Journal of Immunology, 2005, 175, 4137-4147.	0.4	72
13	Processing of a Multiple Membrane Spanning Epstein-Barr Virus Protein for Cd8+T Cell Recognition Reveals a Proteasome-Dependent, Transporter Associated with Antigen Processingâ€“Independent Pathway. Journal of Experimental Medicine, 2001, 194, 1053-1068.	4.2	68
14	The role of tetraspanin CD63 in antigen presentation via MHC class II. European Journal of Immunology, 2011, 41, 2556-2561.	1.6	68
15	A Role for Intercellular Antigen Transfer in the Recognition of EBV-Transformed B Cell Lines by EBV Nuclear Antigen-Specific CD4+T Cells. Journal of Immunology, 2006, 177, 3746-3756.	0.4	65
16	A novel latent membrane 2 transcript expressed in Epstein-Barr virusâ€“positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood, 2010, 116, 3695-3704.	0.6	63
17	Epstein-Barr Virus Evades CD4+ T Cell Responses in Lytic Cycle through BZLF1-mediated Downregulation of CD74 and the Cooperation of vBcl-2. PLoS Pathogens, 2011, 7, e1002455.	2.1	61
18	The T-cell Response to Epstein-Barr Virusâ€“New Tricks From an Old Dog. Frontiers in Immunology, 2019, 10, 2193.	2.2	61

#	Article	IF	Citations
19	EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines. Journal of Immunology, 2008, 180, 1643-1654.	0.4	58
20	Identification of Cytomegalovirus-Specific Cytotoxic T Lymphocytes In Vitro Is Greatly Enhanced by the Use of Recombinant Virus Lacking the US2 to US11 Region or Modified Vaccinia Virus Ankara Expressing Individual Viral Genes. Journal of Virology, 2005, 79, 2869-2879.	1.5	56
21	Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. Journal of Global Health, 2020, 10, 010405.	1.2	56
22	Infectious agents in human cancers: Lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV. Cancer Letters, 2011, 305, 263-278.	3.2	50
23	Identification of a TAP-Independent, Immunoproteasome-Dependent CD8 + T-Cell Epitope in Epstein-Barr Virus Latent Membrane Protein 2. Journal of Virology, 2003, 77, 2757-2761.	1.5	48
24	Heterologous prime-boost vaccination protects against EBV antigenâ€“expressing lymphomas. Journal of Clinical Investigation, 2019, 129, 2071-2087.	3.9	48
25	Molecular Epidemiology of Outbreak of Respiratory Syncytial Virus within Bone Marrow Transplantation Unit. Journal of Clinical Microbiology, 2001, 39, 801-803.	1.8	38
26	CD4 and CD8 T cell responses to tumour-associated Epsteinâ€“Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunology, Immunotherapy, 2008, 57, 963-975.	2.0	38
27	Robust T-cell stimulation by Epstein-Barr virusâ€“transformed B cells after antigen targeting to DEC-205. Blood, 2013, 121, 1584-1594.	0.6	38
28	Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination. PLoS Pathogens, 2016, 12, e1005549.	2.1	36
29	The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery. IScience, 2021, 24, 103215.	1.9	35
30	Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8 + T Cells as the Principal Effectors and a Novel CD4 + T-Cell Reactivity. Journal of Virology, 2005, 79, 5477-5488.	1.5	33
31	EBV-Specific CD4+ T Cell Clones Exhibit Vigorous Allogeneic Responses. Journal of Immunology, 2006, 177, 1427-1433.	0.4	31
32	Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. Chinese Clinical Oncology, 2016, 5, 23-23.	0.4	30
33	T Cell Detection of a B-Cell Tropic Virus Infection: Newly-Synthesised versus Mature Viral Proteins as Antigen Sources for CD4 and CD8 Epitope Display. PLoS Pathogens, 2009, 5, e1000699.	2.1	28
34	Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects. Cancers, 2019, 11, 1115.	1.7	28
35	EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the Epsteinâ€“Barr virus. Nature Biomedical Engineering, 2017, 1, .	11.6	27
36	Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature. Journal of Global Health, 2020, 10, 010404.	1.2	27

#	Article	IF	Citations
37	CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virusâ€“transformed B cells. Blood, 2009, 114, 807-815.	0.6	25
38	T-Cell Responses to EBV. Current Topics in Microbiology and Immunology, 2015, 391, 325-353.	0.7	25
39	Predictors of Epstein-Barr virus serostatus in young people in England. BMC Infectious Diseases, 2019, 19, 1007.	1.3	25
40	Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. PLoS ONE, 2017, 12, e0184841.	1.1	18
41	Autophagy in herpesvirus immune control and immune escape. Herpesviridae, 2011, 2, 2.	2.7	17
42	Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. Cardiovascular Research, 2022, 118, 3085-3096.	1.8	17
43	BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines. Blood Advances, 2020, 4, 356-366.	2.5	16
44	Downâ€regulation of <scp>LPA</scp> receptor 5 contributes to aberrant <scp>LPA</scp> signalling in <scp>EBV</scp>â€associated nasopharyngeal carcinoma. Journal of Pathology, 2015, 235, 456-465.	2.1	15
45	Autophagy and immunity â€“ insights from human herpesviruses. Frontiers in Immunology, 2012, 3, 170.	2.2	13
46	Modelling the dynamics of EBV transmission to inform a vaccine target product profile and future vaccination strategy. Scientific Reports, 2019, 9, 9290.	1.6	11
47	Nuclear shelter: The influence of subcellular location on the processing of antigens by macroautophagy. Autophagy, 2010, 6, 560-561.	4.3	10
48	Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. Scientific Reports, 2021, 11, 4030.	1.6	10
49	T cell-based therapies for EBV-associated malignancies. Expert Opinion on Biological Therapy, 2004, 4, 11-21.	1.4	9
50	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABCâ€subtype diffuse large Bâ€cell lymphoma. Journal of Pathology, 2019, 248, 142-154.	2.1	8
51	Factors associated with cytomegalovirus serostatus in young people in England: a cross-sectional study. BMC Infectious Diseases, 2020, 20, 875.	1.3	7
52	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 8229.	1.8	7
53	LRR-protein RNH1 dampens the inflammasome activation and is associated with COVID-19 severity. Life Science Alliance, 2022, 5, e202101226.	1.3	7
54	Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors. PLoS Pathogens, 2021, 17, e1010137.	2.1	7

#	Article	IF	Citations
55	Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery. Cancers, 2021, 13, 5519.	1.7	6
56	Antigens and Autophagy: The Path Less Travelled?. Autophagy, 2007, 3, 60-62.	4.3	4
57	The Innate and Adaptive Immune Landscape of SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children (MIS-C) from Acute Disease to Recovery. SSRN Electronic Journal, 0, , .	0.4	0
58	DNA and modified vaccinia Ankara primeâ€“boost vaccination generates strong CD8 + T cell responses against minor histocompatibility antigen HAâ€1. British Journal of Haematology, 2021, 195, 433-446.	1.2	0